Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies

被引：0
|
作者：
Deprimo, Samuel E.
Toner, Guy
Mitchell, Paul
De Boer, Richard
Gibbs, Peter
Hicks, Rodney
McArthur, Grant
Brega, Nicoletta
McCarthy, Timothy
Bello, Carlo
机构：
[1] Pfizer Global R&D, La Jolla, CA USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Austin Hosp, Melbourne, Vic, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Pfizer Srl, Milan, Italy
[6] Pfizer Inc, Groton, CT 06340 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Assessment of tumor perfusion by (oxygen-15)-water PET imaging during treatment with sunitinib malate (SU11248) in patients with advanced malignancies
    Mitchell, P
    Scott, AM
    O'Keefe, G
    Saunder, T
    Hicks, RJ
    Poon, A
    Baum, C
    Brega, N
    McCarthy, T
    Toner, G
    ANNALS OF ONCOLOGY, 2006, 17 : 32 - 33
  • [2] Tumor perfusion as assessed by (oxygen-15)-water PET imaging during treatment with sunitinib malate (SU11248) in patients with advanced malignancies.
    Scott, AM
    Mitchell, P
    O'Keefe, G
    Saunder, T
    Hicks, RJ
    Poon, A
    Baum, C
    Brega, N
    McCarthy, T
    Toner, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9129S - 9129S
  • [3] Sunitinib malate (SU11248) - Efficacy in renal cell carcinoma (RCC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 287 - 287
  • [4] Pharmacokinetics (PK) of sunitinib malate (SU11248) in subjects with hepatic impairment
    Bello, Carlo L.
    Garrett, May
    Smeraglia, John
    Sherman, Laurie
    Ryan, Bob
    Toh, Melvin
    ANNALS OF ONCOLOGY, 2006, 17 : 148 - 148
  • [5] The effect of rifampin on the pharmacokinetics of sunitinib malate (SU11248) in Caucasian and Japanese populations
    Bello, C.
    Houk, B.
    Sherman, L.
    Sarapa, N.
    Smeraglia, J.
    Huang, X.
    Klamerus, K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 430 - 430
  • [6] Patients with imatinib mesylate-resistant GIST exhibit durable responses to sunitinib malate (SU11248)
    Morgan, J. A.
    Demetri, G. D.
    Fletcher, J. A.
    George, S.
    Desai, J.
    Maki, R. G.
    Fletcher, C. D.
    Scheu, K.
    Baum, C.
    Heinrich, M. C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 421 - 421
  • [7] Rifampin reduces exposure to sunitinib malate (SU11248) in Caucasian and Japanese populations.
    Bello, CL
    Houk, B
    Sarapa, N
    Smeraglia, J
    Huang, X
    Klamerus, KJ
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S72 - S72
  • [8] The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer
    DePrimo, S.
    Bello, C.
    Smeraglia, J.
    Shalinsky, D.
    Freddo, J.
    Baum, C.
    Rini, R.
    Michaelson, M.
    Motzer, R.
    Spinella, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 420 - 420
  • [9] A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC).
    Ronnen, E. A.
    Kondagunta, G. V.
    Lau, C.
    Fischer, P.
    Ginsberg, M. S.
    Baum, M.
    Kim, S. T.
    Chen, I.
    Baum, C. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 225S - 225S
  • [10] Sunitinib malate (SU11248) may be administered to patients with advanced and metastatic solid tumors on a 2/1 schedule with no significant accumulation between cycles
    Bello, Carlo L.
    Hect, J. Randolph
    Kabbinavar, Fairooz
    Rosen, Peter
    Pegram, Mark
    Baum, Charles
    Britten, Carolyn
    CANCER RESEARCH, 2006, 66 (08)
12345